Dr. Moncef Slaoui, GSK Chairman of vaccines, speaks with CNBC's Meg Tirrell about bioelectronic medicine and the new joint effort between GSK and Alphabet.
GlaxoSmithKline and Alphabet's life sciences unit are creating a new company focused on fighting diseases.
CNBC's Meg Tirrell breaks down GlaxoSmithKline's quarterly results and provides highlights from CEO Andrew Witty comments to CNBC Europe on Brexit.
Andrew Witty, CEO of GlaxoSmithKline, says the firm has been investing in bio electronic medicine for the last few years.
Kevin O'Leary isn't interested in buying what he considers to be over-regulated, "toxic waste" European bank stocks.
Kevin O’Leary says now is the buying opportunity of a lifetime in Europe.
As the world tries to make sense of the U.K.'s historic vote, three sectors could be especially hard hit.
Companies and people are issuing statements about the United Kingdom's decision to leave the European Union. We've got the latest list.
Inovio's Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin.
Some common weight-loss drugs seem to work better than others, according to a new study in a respected medical journal.
Some of the names on the move ahead of the open.
European stocks closed sharply lower on Monday amid a global selloff, as uncertainty over a possible "Brexit" and looming central bank meetings shook markets.
Bookmakers, sportswear and travel seem a safe bet to profit from a large sporting event, but are they the best stocks to hold?
CNBC's Meg Tirrell reports on a new gene therapy to help blind people.
A gene therapy from Spark Therapeutics is offering patients with a rare genetic retinal disease that causes blindness some hope.
Scientists are working on a new treatment for depression and PTSD: deep-brain stimulation.
When we think about taking medicines, we imagine popping a pill, or receiving a shot. But a new approach would leverage the body's electrical signals.
European markets finished mostly mixed on Thursday, as investors digested the latest slew of earnings amid a rise in oil prices.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Andrew Witty, GlaxoSmithKline CEO, discusses drug pricing in the United States, innovations in health care, & more.